SAN DIEGO, July 28, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and pending in the District of New Jersey – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' executives with violations of the Securities Exchange Act of 1934. A subsequently filed ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trial for RP-A501, which resulted in serious adverse events, including patient death [1][4][5]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501 while concealing material adverse facts, including the known risks of serious adverse events [4]. - It is alleged that the company amended the trial protocol to include a new immunomodulatory agent without informing shareholders of this critical update [4]. - Following the announcement of a clinical hold by the FDA due to a serious adverse event resulting in a patient's death, the stock price of Rocket Pharmaceuticals fell significantly [5]. Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7].